Fenofibrate in the management of AbdoMinal aortic anEurysm (FAME)

大约5%的60岁以上的男性和1%的女性会出现腹主动脉衰弱。目前动脉衰弱的治疗主要集中在手术上，没有有效的药物可用。在这项研究中，我们将评估在临床前测试中限制动脉弱化的药物是否也显示出抑制患者动脉损伤重要过程的证据。我们相信，这是评估一种有前景的新疗法的关键一步。

Approximately 5% of men and 1% of women aged over 60 years develop weakening of the main abdominal artery. Currently the management of artery weakening is focused on surgery with no effective medications available. In this study we will assess whether a drug which limits artery weakening in pre-clinical testing also shows evidence of inhibiting processes important in artery damage in patients. We believe this is a critical next step in the assessment of a promising new treatment.